Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulations. With the publication of this announcement, this information is now considered to be in the public domain.
12 May 2022
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Substantial contract win for Proteome Sciences
London, 12 May, 2022. Proteome Sciences is pleased to announce that the Company has secured a contract from a major US academic group to evaluate changes on the proteome and phospho-proteome of tissue and blood samples taken from persons with and without a neurodegenerative disease. The contract value is in excess of £0.5m and we expect the study to be completed this year.
Commenting on the contract, Richard Dennis, Chief Commercial Officer of Proteome Sciences said:
"We are pleased that the SysQuant workflows that we offer has been selected by our client to quantitate the proteomic/phosphoproteomic changes in these research samples. By using the TMTproÔ reagents we are able to analyse 17 samples and one reference in one mass spectrometry experiment, so are able to deliver data from this large sample set in a timely manner and still be able to better quantitate smaller proteomic differences."
- Ends -
For further information:
| Proteome Sciences plc
| |
| Richard Dennis, Chief Commercial Officer Dr Mariola Soehngen, Chief Executive Officer Dr Ian Pike, Chief Scientific Officer
| Tel: +44 (0)20 7043 2116 |
| Allenby Capital Limited (AIM Nominated Adviser & Broker) | |
| John Depasquale/ Jeremy Porter Tel: +44 (0)20 3328 5656 | |
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.
The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
